ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.350,38
0,92%
S&P 500
5.996,66
1,00%
US Dollar vs BRL
6,0921
0,19%
Bitcoin
108.433,63
5,16%
Brent Oil
79,675
-0,67%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Beam Therapeutics Inc (BEAM)

  7. Beam Therapeutics Inc (BEAM) Notícias

BEAM

Beam Therapeutics (BEAM)

Beam Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BEAM
DataHoraFonteTítuloCódigoCompanhia
13/01/202509:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
13/01/202509:00GlobeNewswire Inc.Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated CatalystsNASDAQ:BEAMBeam Therapeutics Inc
06/01/202519:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
30/12/202421:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
19/12/202418:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
17/12/202409:00GlobeNewswire Inc.Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
08/12/202415:45GlobeNewswire Inc.Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
07/12/202413:30GlobeNewswire Inc.Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
06/12/202409:00GlobeNewswire Inc.Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerNASDAQ:BEAMBeam Therapeutics Inc
04/12/202409:00GlobeNewswire Inc.Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial LeaderNASDAQ:BEAMBeam Therapeutics Inc
12/11/202418:01GlobeNewswire Inc.Beam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
05/11/202411:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BEAMBeam Therapeutics Inc
05/11/202411:00GlobeNewswire Inc.Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
05/11/202408:30GlobeNewswire Inc.Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsNASDAQ:BEAMBeam Therapeutics Inc
29/10/202407:30GlobeNewswire Inc.Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
21/10/202417:11Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BEAMBeam Therapeutics Inc
06/08/202407:30GlobeNewswire Inc.Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial ResultsNASDAQ:BEAMBeam Therapeutics Inc
15/07/202407:30GlobeNewswire Inc.Beam Therapeutics Announces Transition of Chief Financial OfficerNASDAQ:BEAMBeam Therapeutics Inc
26/06/202407:30GlobeNewswire Inc.Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)NASDAQ:BEAMBeam Therapeutics Inc
14/06/202404:00GlobeNewswire Inc.Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell DiseaseNASDAQ:BEAMBeam Therapeutics Inc
30/05/202407:30GlobeNewswire Inc.Beam Therapeutics to Participate in Jefferies Global Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
14/05/202417:00GlobeNewswire Inc.Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressNASDAQ:BEAMBeam Therapeutics Inc
08/05/202407:30GlobeNewswire Inc.Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
07/05/202407:30GlobeNewswire Inc.Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial ResultsNASDAQ:BEAMBeam Therapeutics Inc
26/03/202407:30GlobeNewswire Inc.Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)NASDAQ:BEAMBeam Therapeutics Inc
28/02/202408:30GlobeNewswire Inc.Beam Therapeutics to Participate in Upcoming March 2024 Investor ConferencesNASDAQ:BEAMBeam Therapeutics Inc
27/02/202409:40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BEAMBeam Therapeutics Inc
27/02/202409:22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BEAMBeam Therapeutics Inc
27/02/202408:30GlobeNewswire Inc.Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated MilestonesNASDAQ:BEAMBeam Therapeutics Inc
05/02/202408:30GlobeNewswire Inc.Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:BEAMBeam Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BEAM

Seu Histórico Recente

FX
TWDUSD
TWD vs US Dollar
TG
A3LHYD
AT & T
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados